New Risk • Jul 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (9.1% average weekly change). Announcement • Jun 30
Haisco Pharmaceutical Group Co., Ltd. to Report First Half, 2026 Results on Aug 27, 2026 Haisco Pharmaceutical Group Co., Ltd. announced that they will report first half, 2026 results on Aug 27, 2026 Announcement • Jun 02
Haisco Pharmaceutical Group Receives U.S. FDA Marketing Approval For Cipepofol (CYPSEDO) Injection Haisco Pharmaceutical Group has officially received marketing approval from the U.S. Food and Drug Administration (FDA) for Cipepofol (CYPSEDO) Injection, a Class 1 innovative intravenous anesthetic independently developed by Haisco Pharmaceutical Group, becoming the first China-originated innovative intravenous anesthetic to enter the global market. Cipepofol (Chinese trade name: Sishuning) is China's first independently developed Class 1 innovative intravenous anesthetic with global independent intellectual property rights. It has been approved in China for sedation and anesthesia in non-tracheal intubation surgeries/procedures, induction and maintenance of general anesthesia, and sedation during mechanical ventilation in the intensive care unit. In September 2025, its approval was further expanded to include the induction and maintenance of general anesthesia in children and adolescents. The development of Cipepofol dates back to 2012. Haisco's R&D team tackled numerous challenges to refine the molecular structure. By introducing a chiral cyclopropyl group and conducting thousands of screenings and safety evaluations, they successfully developed a Class 1 new drug that demonstrated favorable efficacy and safety profiles. Results from clinical studies conducted both domestically and internationally showed that, while retaining the advantages of rapid onset and complete recovery, Cipepofol significantly reduced the incidence of intraoperative respiratory depression and cardiovascular adverse reactions, as well as injection pain. With a lower risk of respiratory depression, more stable hemodynamics, milder injection pain, and individualized care for elderly and pediatric patients, Cipepofol not only makes "comfortable treatment" more compassionate—directly addressing patients' desire for a pain-free anesthesia induction and reducing their fear of surgery—but also substantially enhances the comfort and safety of the diagnosis and treatment process on both physiological and psychological levels, while greatly improving the accuracy and success rate of physicians' diagnoses and treatments. In December 2020, Cipepofol was officially approved for marketing by the National Medical Products Administration (NMPA), ushering in a new chapter in clinical comfortable anesthesia. Subsequently, multiple indications were approved in succession, including induction of general anesthesia, fiberoptic bronchoscopy, and sedation during intensive care. In September 2025, the dosage and administration for the induction and maintenance of general anesthesia in children and adolescents were approved, further broadening its clinical application scenarios. As of May 2026, Cipepofol has been incorporated into the recommendations of over 20 guidelines and consensus documents, as well as into textbooks for higher education under China's 14th Five-Year Plan, and has been included in the National Reimbursement Drug List (NRDL). To date, it has been adopted by over 3,300 medical institutions, cumulatively benefiting more than 40 million patient visits. After receiving FDA clearance to conduct clinical trials in 2021, Cipepofol was granted a waiver for Phase II trials in the United States and advanced directly to pivotal Phase III trials. All clinical studies were completed in 2024, yielding superior results in a head-to-head comparison against the standard of care. In July 2025, the New Drug Application (NDA) for Cipepofol was formally accepted by the U.S. FDA. Haisco is actively advancing its commercialization in the United States and other regions through collaborations. The company will also consider initiating a marketing authorization application in Europe at an appropriate time. Announcement • Apr 12
Haisco Pharmaceutical Group Co., Ltd., Annual General Meeting, May 06, 2026 Haisco Pharmaceutical Group Co., Ltd., Annual General Meeting, May 06, 2026, at 14:00 China Standard Time. Location: 3F, Office Building, No. 136, Baili Road, Cross-Strait Science and Technology Industrial Development Park, Wenjiang District, Chengdu, Sichuan China Announcement • Mar 31
Haisco Pharmaceutical Group Co., Ltd. to Report Q1, 2026 Results on Apr 27, 2026 Haisco Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2026 results on Apr 27, 2026 Announcement • Dec 31
Haisco Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2025 Results on Apr 13, 2026 Haisco Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2025 results on Apr 13, 2026 Announcement • Sep 30
Haisco Pharmaceutical Group Co., Ltd. to Report Q3, 2025 Results on Oct 30, 2025 Haisco Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025 Announcement • Jul 02
Haisco Pharmaceutical Group Co., Ltd. to Report First Half, 2025 Results on Aug 23, 2025 Haisco Pharmaceutical Group Co., Ltd. announced that they will report first half, 2025 results on Aug 23, 2025 Announcement • Apr 15
Haisco Pharmaceutical Group Co., Ltd. Proposes Final Cash Dividend for the Year 2024 Haisco Pharmaceutical Group Co., Ltd. proposed final cash dividend/10 shares (tax included) of CNY 1.35000000 for the year 2024. Announcement • Apr 14
Haisco Pharmaceutical Group Co., Ltd., Annual General Meeting, May 06, 2025 Haisco Pharmaceutical Group Co., Ltd., Annual General Meeting, May 06, 2025, at 14:00 China Standard Time. Location: 3F, Office Building, No. 136, Baili Road, Cross-Strait Science and Technology Industrial Development Park, Wenjiang District, Chengdu, Sichuan China Announcement • Mar 31
Haisco Pharmaceutical Group Co., Ltd. to Report Q1, 2025 Results on Apr 25, 2025 Haisco Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025 Announcement • Feb 28
Haisco Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 1.3652567 billion in funding Haisco Pharmaceutical Group Co., Ltd. announced a private placement of not more than 70,000,000 A shares for the gross proceeds of CNY 1,365,256,700 on February 27, 2025. The transaction will include participation from not more than 35 specific investors. The shares will not be transferrable within 6 months from the date of completion of the issuance. The transaction has been approved by the shareholders of the company in the 24th meeting of the 5th board of directors and the 13th meeting of the 5th supervisory board. The transaction is subjected to approval by the company's general meeting of shareholders, review and approval by the Shenzhen Stock Exchange, and registration consent by the China Securities Regulatory Commission. The validity for the approval is of 12 months from the date the company's general meeting of shareholders approves the relevant proposals for this issuance. Announcement • Jan 18
Haisco Pharmaceutical Group Co., Ltd. Approves Profit Distribution Plan for Third Quarter 2024, Payable on 24 January 2025 Haisco Pharmaceutical Group Co., Ltd. at the Extraordinary General Meeting held on 15 January 2025 approved 2024 third quarter profit distribution plan. Cash dividend per 10 shares (A shares): (tax included) of CNY 1.35000000. Record date: 23 January 2025; Ex-date: 24 January 2025; Payment date: 24 January 2025. Announcement • Jan 02
Haisco Pharmaceutical Group Co., Ltd. Proposes Dividend for Third Quarter of 2024 Haisco Pharmaceutical Group Co., Ltd. proposed Cash dividend/10 shares (tax included) of CNY1.35000000 for third quarter of 2024. Announcement • Dec 31
Haisco Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2024 Results on Apr 12, 2025 Haisco Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2024 results on Apr 12, 2025 New Risk • Oct 31
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 25% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (332% cash payout ratio). Large one-off items impacting financial results. Reported Earnings • Oct 30
Third quarter 2024 earnings released: EPS: CN¥0.19 (vs CN¥0.11 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.19 (up from CN¥0.11 in 3Q 2023). Revenue: CN¥1.06b (up 5.0% from 3Q 2023). Net income: CN¥217.1m (up 73% from 3Q 2023). Profit margin: 20% (up from 12% in 3Q 2023). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Sep 30
Haisco Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024 Haisco Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024 Announcement • Sep 10
Haisco Pharmaceutical Group Co., Ltd. Announces Interim Cash Dividend on A Shares for the Year 2024, Payable on 18 September 2024 Haisco Pharmaceutical Group Co., Ltd. announced interim cash dividend of CNY 1.45 per 10 shares on A shares (tax included) for the year 2024. Record date: 13 September 2024, Ex-date: 18 September 2024 and Payment date: 18 September 2024. Announcement • Sep 07
Haisco Pharmaceutical Group Co., Ltd. Interim Cash Dividend for 2024 Haisco Pharmaceutical Group Co., Ltd. at the Extraordinary General Meeting of 2024 on 05 September 2024 approved 2024 interim profit distribution plan. The detailed profit distribution plan is as follows: Cash dividend per 10 shares (tax included) of CNY 1.45000000. Announcement • Aug 17
Haisco Pharmaceutical Group Co., Ltd. Proposes Interim Dividend for the First Half of 2024 Haisco Pharmaceutical Group Co., Ltd. proposed interim cash dividend of CNY 1.45000000 per 10 shares (tax included) for the first half of 2024. Reported Earnings • Aug 16
Second quarter 2024 earnings released: EPS: CN¥0.068 (vs CN¥0.037 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.068 (up from CN¥0.037 in 2Q 2023). Revenue: CN¥934.5m (up 25% from 2Q 2023). Net income: CN¥72.8m (up 57% from 2Q 2023). Profit margin: 7.8% (up from 6.2% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. Announcement • Jun 29
Haisco Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 16, 2024 Haisco Pharmaceutical Group Co., Ltd. announced that they will report first half, 2024 results on Aug 16, 2024 New Risk • Apr 21
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. Cash payout ratio: 346% Dividend yield: 0.8% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (346% cash payout ratio). Large one-off items impacting financial results. Reported Earnings • Apr 20
Full year 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.26 in FY 2022) Full year 2023 results: EPS: CN¥0.27 (up from CN¥0.26 in FY 2022). Revenue: CN¥3.36b (up 11% from FY 2022). Net income: CN¥295.1m (up 6.5% from FY 2022). Profit margin: 8.8% (down from 9.2% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Announcement • Mar 30
Haisco Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 20, 2024 Haisco Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2024 results on Apr 20, 2024 Valuation Update With 7 Day Price Move • Feb 09
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥23.48, the stock trades at a forward P/E ratio of 64x. Average forward P/E is 17x in the Pharmaceuticals industry in China. Total returns to shareholders of 15% over the past three years. Announcement • Dec 30
Haisco Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 18, 2024 Haisco Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2023 results on Apr 18, 2024 New Risk • Nov 06
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 23% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (3.6% increase in shares outstanding). Reported Earnings • Nov 01
Third quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.031 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.11 (up from CN¥0.031 in 3Q 2022). Revenue: CN¥1.01b (up 19% from 3Q 2022). Net income: CN¥125.7m (up 278% from 3Q 2022). Profit margin: 12% (up from 3.9% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Announcement • Aug 29
Haisco Pharmaceutical Group Co., Ltd. Announces Management Changes Haisco Pharmaceutical Group Co., Ltd. at its 2nd Extraordinary General Meeting of 2023 on 25 August 2023, during which the following proposal(s) was/were approved: Election and nomination of non-independent directors, cumulative voting system applicable: Wang Junmin, Fan Xiulian, Zheng Wei, Yan Pangke. Election and nomination of independent directors, cumulative voting system applicable: Yue Lin and Cao Chuande. Election of shareholder supervisors, cumulative voting system applicable: Liang Yuan and Sun Tao. Reported Earnings • Aug 17
Second quarter 2023 earnings released: EPS: CN¥0.037 (vs CN¥0.052 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.037. Revenue: CN¥746.1m (up 8.9% from 2Q 2022). Net income: CN¥46.3m (up 6.2% from 2Q 2022). Profit margin: 6.2% (down from 6.4% in 2Q 2022). The decrease in margin was driven by higher expenses. New Risk • Aug 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.4% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Shareholders have been diluted in the past year (3.6% increase in shares outstanding). Reported Earnings • Apr 18
Full year 2022 earnings released: EPS: CN¥0.26 (vs CN¥0.32 in FY 2021) Full year 2022 results: EPS: CN¥0.26 (down from CN¥0.32 in FY 2021). Revenue: CN¥3.02b (up 8.7% from FY 2021). Net income: CN¥277.0m (down 20% from FY 2021). Profit margin: 9.2% (down from 12% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Jun Le was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥0.031 (vs CN¥0.043 loss in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.031 (up from CN¥0.043 loss in 3Q 2021). Revenue: CN¥849.4m (up 34% from 3Q 2021). Net income: CN¥33.2m (up CN¥78.4m from 3Q 2021). Profit margin: 3.9% (up from net loss in 3Q 2021). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Reported Earnings • Aug 18
Second quarter 2022 earnings released: EPS: CN¥0.052 (vs CN¥0.031 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.052 (up from CN¥0.031 in 2Q 2021). Revenue: CN¥685.3m (up 25% from 2Q 2021). Net income: CN¥43.6m (up 32% from 2Q 2021). Profit margin: 6.4% (up from 6.0% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 46%, compared to a 23% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Reported Earnings • Apr 28
Full year 2021 earnings released: EPS: CN¥0.32 (vs CN¥0.59 in FY 2020) Full year 2021 results: EPS: CN¥0.32 (down from CN¥0.59 in FY 2020). Revenue: CN¥2.77b (down 17% from FY 2020). Net income: CN¥345.1m (down 46% from FY 2020). Profit margin: 12% (down from 19% in FY 2020). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 25%, compared to a 26% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Board Change • Apr 27
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. Independent Director Jun Le is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Valuation Update With 7 Day Price Move • Jan 27
Investor sentiment deteriorated over the past week After last week's 17% share price decline to CN¥17.97, the stock trades at a forward P/E ratio of 52x. Average forward P/E is 22x in the Pharmaceuticals industry in China. Total returns to shareholders of 88% over the past three years. Valuation Update With 7 Day Price Move • Nov 10
Investor sentiment improved over the past week After last week's 20% share price gain to CN¥21.02, the stock trades at a forward P/E ratio of 61x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 68% over the past three years. Reported Earnings • Oct 31
Third quarter 2021 earnings released: CN¥0.043 loss per share (vs CN¥0.17 profit in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: CN¥635.1m (down 31% from 3Q 2020). Net loss: CN¥45.2m (down 126% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 28
Second quarter 2021 earnings released: EPS CN¥0.031 (vs CN¥0.09 in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥548.1m (down 37% from 2Q 2020). Net income: CN¥33.0m (down 67% from 2Q 2020). Profit margin: 6.0% (down from 12% in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 29
First quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.12 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥728.1m (up 24% from 1Q 2020). Net income: CN¥287.3m (up 124% from 1Q 2020). Profit margin: 40% (up from 22% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 26% per year, which means it is significantly lagging earnings growth. Reported Earnings • Mar 27
Full year 2020 earnings released: EPS CN¥0.59 (vs CN¥0.46 in FY 2019) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: CN¥3.33b (down 15% from FY 2019). Net income: CN¥636.6m (up 29% from FY 2019). Profit margin: 19% (up from 13% in FY 2019). Post-clinical trial products Approved (during full year): 5 Over the last 3 years on average, earnings per share has increased by 31% per year whereas the company’s share price has increased by 30% per year. Valuation Update With 7 Day Price Move • Mar 10
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥23.74, the stock is trading at a trailing P/E ratio of 40.9x, up from the previous P/E ratio of 34.7x. This compares to an average P/E of 29x in the Pharmaceuticals industry in China. Total returns to shareholders over the past three years are 122%. Is New 90 Day High Low • Mar 06
New 90-day high: CN¥22.12 The company is up 7.0% from its price of CN¥20.59 on 04 December 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. Valuation Update With 7 Day Price Move • Feb 06
Investor sentiment improved over the past week After last week's 21% share price gain to CN¥20.89, the stock is trading at a trailing P/E ratio of 43.5x, up from the previous P/E ratio of 36x. This compares to an average P/E of 29x in the Pharmaceuticals industry in China. Total returns to shareholders over the past three years are 123%. Is New 90 Day High Low • Jan 04
New 90-day low: CN¥17.25 The company is down 20% from its price of CN¥21.61 on 30 September 2020. The Chinese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period. Is New 90 Day High Low • Dec 16
New 90-day low: CN¥19.06 The company is down 18% from its price of CN¥23.23 on 18 September 2020. The Chinese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period. Is New 90 Day High Low • Nov 09
New 90-day low: CN¥21.43 The company is down 21% from its price of CN¥27.02 on 11 August 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 12% over the same period. Reported Earnings • Oct 30
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥513.4m, up 24% from the prior year. Total revenue was CN¥3.33b over the last 12 months, down 23% from the prior year. Is New 90 Day High Low • Sep 24
New 90-day low: CN¥21.91 The company is down 16% from its price of CN¥26.10 on 24 June 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 6.0% over the same period.